跳转至内容
Merck
CN

CDS023389

Sigma-Aldrich

达沙替尼

别名:

N-(2-氯-6-甲基苯基)-2-[[6-[4-(2-羟乙基)-1-哌嗪基]-2-甲基-4-嘧啶基]氨基]-5-噻唑甲酰胺

登录查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C22H26ClN7O2S
化学文摘社编号:
302962-49-8
分子量:
488.01
MDL编号:
MFCD11046566
UNSPSC代码:
12352200
PubChem化学物质编号:
329796700

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

描述

AldrichCPR

表单

solid

储存温度

-10 to -25°C

SMILES字符串

CC1=NC(NC2=NC=C(C(NC3=C(C=CC=C3Cl)C)=O)S2)=CC(N4CCN(CC4)CCO)=N1

InChI

1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)

InChI key

ZBNZXTGUTAYRHI-UHFFFAOYSA-N

基因信息

human ... ABL1(25), BLK(640), EPHA2(1969), FGR(2268), FRK(2444), FYN(2534), HCK(3055), KIT(3815), LCK(3932), LYN(4067), PDGFRB(5159), SRC(6714), SRMS(6725), YES1(7525)

正在寻找类似产品? 访问 产品对比指南

其他说明

请注意，Sigma-Aldrich 向早期发现研究人员提供该产品，作为独特化学品集合的一部分。Sigma-Aldrich 不收集本品的分析数据。买方负责确认产品标识和/或纯度。所有销售均为最终产品。

尽管 SIGMA-ALDRICH 中包含任何违反条款的条款和标准条款和条件以及 SIGMA-ALDRICH 与买方之间的协议，但 SIGMA-ALDRICH “按原样”销售本产品，且不对本产品做出任何声明或保证，包括任何 (A) 适销性保证；(B) 对某一特定用途的适合性的保证；(C) 防止侵犯第三方知识产权的保证；无论侵犯活动是由法律、交易过程、履行过程、贸易惯例还是其他原因引起的。

警示用语：

Danger

危险分类

Aquatic Chronic 1 - Carc. 2 - Eye Dam. 1 - Repr. 2 - Skin Irrit. 2 - STOT RE 1

靶器官

Gastro-intestinal system

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Lei Liu et al.
Journal of pineal research, 67(2), e12588-e12588 (2019-05-30)
Chordoma is an extremely rare malignant bone tumor with a high rate of relapse. While cancer stem cells (CSCs) are closely associated with tumor recurrence, which depend on its capacity to self-renew and induce chemo-/radioresistance, whether and how CSCs participate
Maja Kim Kuepper et al.
Leukemia, 33(8), 1964-1977 (2019-03-08)
Tyrosine kinase inhibitor (TKI) therapy effectively blocks oncogenic Bcr-Abl signaling and induces molecular remission in the majority of CML patients. However, the disease-driving stem cell population is not fully targeted by TKI therapy in the majority of patients, and leukemic
Kenta Mukaihara et al.
PloS one, 12(9), e0185321-e0185321 (2017-09-26)
Alveolar soft part sarcoma (ASPS) is an extremely rare metastatic soft tissue tumor with a poor prognosis for which no effective systemic therapies have yet been established. Therefore, the development of novel effective treatment approaches is required. Tyrosine kinases (TKs)
Daniela D'Arcangelo et al.
Oncotarget, 7(47), 77257-77275 (2016-10-21)
Melanoma is the most aggressive skin-cancer, showing high mortality at advanced stages. Platelet Derived Growth Factor Receptor-alpha (PDGFR-alpha) potently inhibits melanoma- and endothelium-proliferation and its expression is significantly reduced in melanoma-biopsies, suggesting that melanoma progression eliminates cells expressing PDGFR-alpha. In
Katherine Tarlock et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 25(16), 5038-5048 (2019-06-12)
KIT mutations (KIT+) are common in core binding factor (CBF) AML and have been associated with varying prognostic significance. We sought to define the functional and clinical significance of distinct KIT mutations in CBF pediatric AML. Following transfection of exon
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持